Bokf Na Sells 3,870 Shares of Stryker Corporation $SYK

Key Points

• Bokf Na trimmed its stake in Stryker by 13.5%, selling 3,870 shares and now holding 24,777 shares valued at about $8.71 million per its latest SEC filing.
• Stryker reported an earnings miss on April 30 — $2.60 EPS vs. $2.98 expected and $6.02B revenue vs. $6.34B expected — while setting FY2026 guidance of $14.90–15.10 EPS (consensus ~14.97).
• Analysts maintain a consensus of "Moderate Buy" with an average price target of $395.48 (16 Buys, 6 Holds), even as the stock trades near $292 with a market cap of ~$111.9B and a 1‑year range of $289.91–$404.87.

Bokf Na lessened its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 13.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,777 shares of the medical technology company's stock after selling 3,870 shares during the period. Bokf Na's holdings in Stryker were worth $8,708,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. United Financial Planning Group LLC bought a new stake in Stryker in the third quarter valued at approximately $27,000. Strive Asset Management LLC bought a new stake in Stryker in the third quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd bought a new stake in Stryker in the third quarter valued at approximately $34,000. Copia Wealth Management raised its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock valued at $40,000 after buying an additional 69 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in Stryker in the fourth quarter valued at approximately $40,000. Institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SYK shares. Citigroup dropped their price objective on Stryker from $420.00 to $385.00 and set a "buy" rating on the stock in a research note on Tuesday, April 7th. Weiss Ratings lowered Stryker from a "hold (c+)" rating to a "hold (c)" rating in a research note on Monday. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Evercore set a $355.00 price objective on Stryker in a research note on Friday, May 1st. Finally, Piper Sandler restated an "overweight" rating on shares of Stryker in a research note on Tuesday, January 27th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $395.48.

Stryker Trading Down 1.1%

Shares of NYSE:SYK opened at $292.13 on Thursday. The company has a market capitalization of $111.88 billion, a P/E ratio of 33.81, a P/E/G ratio of 1.86 and a beta of 0.80. Stryker Corporation has a 1 year low of $289.91 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business's 50 day simple moving average is $342.12 and its 200 day simple moving average is $355.73.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.97 EPS for the current fiscal year.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.